N. Sakiyama

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study

Y. Ohe, A. Hara, H. Hashimoto, 2021, Frontiers in Oncology.

Efficacy and safety of osimertinib in a Japanese compassionate use program

Y. Ohe, N. Yamamoto, H. Horinouchi, 2017, Japanese journal of clinical oncology.

Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant

Y. Ohe, Takeshi Akiyoshi, H. Hashimoto, 2022, European Journal of Clinical Pharmacology.

Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study

Y. Ohe, R. Uozumi, K. Fukunaga, 2021, Frontiers in Oncology.

Safety implications of switching pembrolizumab dosage from 200 mg Q3W to 400 mg Q6W in patients with advanced non-small-cell lung cancer.

Y. Ohe, N. Yamamoto, H. Horinouchi, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study

Y. Ohe, R. Uozumi, K. Fukunaga, 2021, Journal of Cancer.

Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight

Y. Hosomi, Toshiaki Takahashi, N. Yamamoto, 2023, Cancer science.